{"id":36710,"date":"2025-07-04T17:03:49","date_gmt":"2025-07-04T09:03:49","guid":{"rendered":"https:\/\/flcube.com\/?p=36710"},"modified":"2025-07-04T17:03:49","modified_gmt":"2025-07-04T09:03:49","slug":"hangzhou-jiuyuan-announces-nmpa-approval-for-generic-doptelet-in-thrombocytopenia-treatmen","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=36710","title":{"rendered":"Hangzhou Jiuyuan Announces NMPA Approval for Generic Doptelet in Thrombocytopenia Treatmen"},"content":{"rendered":"\n

Hangzhou Jiuyuan Gene Engineering Co., Ltd. (HKG: 2566<\/a>) announced that it has received marketing approval from China\u2019s National Medical Products Administration (NMPA) for its generic version of AkaRx Inc.\u2019s Doptelet (avatrombopag). The drug is now approved for use in adult patients with chronic liver disease-associated thrombocytopenia who are scheduled to undergo elective diagnostic procedures or surgery. It is also approved for adult patients with chronic primary immune thrombocytopenia (ITP) who have had an insufficient response to prior treatments such as corticosteroids or immunoglobulins.<\/p>\n\n\n\n

Mechanism and Advantages<\/strong>
Doptelet, a next-generation oral thrombopoietin receptor agonist (TPO-RA), works by stimulating the proliferation and differentiation of megakaryocytes in bone marrow progenitor cells, thereby promoting platelet production. Key advantages include no dietary restrictions, convenient oral administration, and no need for intravenous injections. These features are expected to significantly improve patient compliance and quality of life.<\/p>\n\n\n\n

Inclusion in National Reimbursement Drug List<\/strong>
The drug has been included in China\u2019s 2025 National Reimbursement Drug List (Category B), which enhances accessibility and affordability for patients.-Fineline Info & Tech<\/a><\/p>\n\n\n\n